New drug duo tested for Tough-to-Treat lung cancer
NCT ID NCT06083857
Summary
This early-stage study is testing whether combining two targeted drugs, amivantamab and tepotinib, can help control advanced non-small cell lung cancer that has specific changes in a gene called MET. The main goals are to find a safe dose and see if the combination shows early signs of shrinking tumors. The study is for adults whose cancer has spread and is no longer responding to surgery or radiation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.